SCHEMBL3015070

SCHEMBL3015070

COc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3ccc(C)cc3)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.43
RAB9A P51151 2/20 0.41
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
PKM P14618 2/20 0.38
NCOA1 Q15788 1/20 0.37
NCOA3 Q9Y6Q9 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
ATM Q13315 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
MAPT P10636 3/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
HTR6 P50406 1/20 0.36
USP2 O75604 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019118 0.93 MAPT (0.41) GBA1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL3006479 0.93 MAPT (0.40) GBA1RAB9AKMT2AMEN1MAPT
SCHEMBL3013002 0.92 SMN1; SMN2 (0.38) GBA1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL3005203 0.90 LTA4H (0.36) GBA1RAB9AKMT2AMEN1MAPT
SCHEMBL3007549 0.90 EDNRA (0.38) GBA1KMT2AMEN1MAPTALDH1A1
SCHEMBL3019256 0.90 TSHR (0.39) RAB9ASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL3007694 0.89 MAPT (0.41) RAB9AKMT2AMEN1PKMSMN1; SMN2
SCHEMBL3002378 0.89 GBA1 (0.46) GBA1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL3018197 0.88 MAPT (0.40) GBA1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL3014518 0.88 MAPT (0.39) GBA1RAB9AKMT2ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GBA1 4/4885RAB9A 2943/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.